

Dear Healthcare Professional,

Daratumumab, the ingredient in DARZALEX FASPRO[®] (daratumumab and hyaluronidase-fihj) and DARZALEX[®] (daratumumab), binds to CD38 on red blood cells (RBCs), which results in a positive indirect antiglobulin test (indirect Coombs test). This may interfere with the ability to accurately detect antibodies to minor histocompatibility antigens in the patient's serum. This effect may persist for up to 6 months after the last treatment. The determination of a patient's ABO and Rh blood type are not impacted.

You can learn more at www.darzalexhcp.com/blood-type.

**In case of emergency, or if you find this document,
please call the contact listed below:**

Doctor, Clinic, Center,
or Hospital Name: _____

24-Hour Emergency

Telephone Number: _____

DARZALEX FASPRO® or DARZALEX® PATIENTS:
Give this to healthcare professionals **BEFORE**
your blood is drawn.

Patient ID Card for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) or DARZALEX® (daratumumab)

Name: _____

I am being treated with one of the following medications:

DARZALEX FASPRO® or DARZALEX®, antibody products



© Janssen Biotech, Inc. 2021 10/21 cp-145987v2



DARZALEX Faspro®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units



DARZALEX®
(daratumumab)
Injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL